- Home
- COLL vs SABR Comparison
COLL vs SABR Comparison
Compare COLL & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COLL | SABR |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.3M | 674.0M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | COLL | SABR |
|---|---|---|
| Price | $24.83 | $1.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 6 |
| Target Price | ★ $44.88 | $2.11 |
| AVG Volume (30 Days) | 613.1K | ★ 8.9M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 283.56 |
| EPS | ★ 0.64 | N/A |
| Revenue | $780,567,000.00 | ★ $3,866,956,000.00 |
| Revenue This Year | $6.73 | $4.70 |
| Revenue Next Year | $1.37 | $4.69 |
| P/E Ratio | $39.01 | ★ N/A |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $21.43 | $0.81 |
| 52 Week High | $50.79 | $2.50 |
Technical Indicators
Market Signals| Indicator | COLL | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 58.75 |
| Support Level | $21.67 | $1.65 |
| Resistance Level | $26.39 | $1.99 |
| Average True Range (ATR) | 0.85 | 0.15 |
| MACD | 0.17 | 0.05 |
| Stochastic Oscillator | 61.74 | 81.01 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.